JLE

Hématologie

MENU

Targeted therapies in diffuse large B-cell lymphomas Volume 27, supplement 1, Mars 2021

Figures


  • Figure 1

Tables

Authors
CHU de Nantes, Nantes, France
* Tirés à part

More than half of newly diagnosed diffuse large B-cell lymphomas (DLBCL) are cured with R-CHOP chemotherapy. Some of these lymphomas have a more aggressive and chemoresistant course, reflecting the molecular and genetic heterogeneity of DLBCL. Approximately 20% of patients have primary refractory disease and 30% of patients relapse despite a complete response. The prognosis of these patients is poor, illustrating the need for new therapeutic strategies. Numerous targeted therapies have been developed in the DLBCL in recent years. These are based on immunotherapy targeting surface antigens (naked, bispecific or conjugated antibodies and CAR-T cells), or on the development of small molecules targeting cell signaling pathways that are constitutively activated in some DLBCL. This review presents the main targets and molecules of therapeutic interest in the treatment of DLBCL.